Oncology Bulletin
Oncology Central
Oncology Central is a free online resource that unites all aspects of oncology to support.
Imaging advanced melanoma tumors receiving pembrolizumab after only 1 week, rather than the standard of 3 months, identified metabolic changes that corresponded with treatment response and progression-free survival.
More diagnostic content:
JOURNAL ARTICLES
Read about the 5-year results from part 1 of the COLUMBUS clinical study, which looked at the combination treatment of encorafenib plus binimetinib for BRAF V600-mutant melanoma patients, in this plain language summary of the trial.
Find out details of a real-world database analysis exploring how adding palbociclib to an aromatase inhibitor could prolong the life of people with metastatic HR+/HER2– breast cancer in routine clinical practice.?
In this interview from Colorectal Cancer Management, Mirjana Efremova (Medical University of Innsbruck, Austria) describes how colorectal cells adapt and change through plasticity. ?
"Progress is impossible without change," George Bernard Shaw once said. It's fantastic to see such advancements in predicting treatment responses for advanced melanoma. For those pushing boundaries, did you know there's a sponsorship opportunity available for the Guinness World Record of Tree Planting? Find out more here: https://bit.ly/TreeGuinnessWorldRecord ????
Absolutely fascinating read! As Steve Jobs once said, "The only way to do great work is to love what you do." Your dedication to advancing melanoma treatment clearly shows this passion ??. Subscribed for more insights! ??